CDMO Blog

Concentration and Reformulation of Cellular Immunotherapies – A Major Downstream Processing Step

An-image-of-the-GE-Sefia-Cell-Processing-SystemCellular immunotherapies (e.g. CAR-T cells) are primarily used as an autologous therapy to treat cancer. As such, these therapies are currently generated in small batches for each patient. To generate enough modified cells for a single treatment, cells are expanded in volumes from 1-10 L. In the final step of downstream processing (DSP) for immunotherapies, cells cultured in large volumes must be concentrated and reformulated into smaller volumes (e.g. 20-100 mL) suitable for delivery to patients.

Read More
Posted: Oct 30, 2019 3:48:28 PM